Pharma boosts pipeline to 39 assets

Sandoz will add up to 10 biosimilars to its pipeline after signing an agreement with Shanghai Henlius Biotech worth up to US$322 million (A$453 million).

To see the whole article, log in or create an account.

Simon Webster